CN105339370B - 用于治疗炎症性疾病的化合物和及其药物组合物 - Google Patents

用于治疗炎症性疾病的化合物和及其药物组合物 Download PDF

Info

Publication number
CN105339370B
CN105339370B CN201480035018.3A CN201480035018A CN105339370B CN 105339370 B CN105339370 B CN 105339370B CN 201480035018 A CN201480035018 A CN 201480035018A CN 105339370 B CN105339370 B CN 105339370B
Authority
CN
China
Prior art keywords
methyl
fluorophenyl
ethyl
amino
imidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480035018.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105339370A (zh
Inventor
N·迪斯若瑞
B·海克曼
R·C·X·布莱斯
A·M·容古
C·佩肖托
X·M·博克
C·G·豪斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CN105339370A publication Critical patent/CN105339370A/zh
Application granted granted Critical
Publication of CN105339370B publication Critical patent/CN105339370B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480035018.3A 2013-06-19 2014-06-12 用于治疗炎症性疾病的化合物和及其药物组合物 Active CN105339370B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361836831P 2013-06-19 2013-06-19
US61/836,831 2013-06-19
PCT/EP2014/062241 WO2014202458A1 (en) 2013-06-19 2014-06-12 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
CN105339370A CN105339370A (zh) 2016-02-17
CN105339370B true CN105339370B (zh) 2017-09-15

Family

ID=50942280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480035018.3A Active CN105339370B (zh) 2013-06-19 2014-06-12 用于治疗炎症性疾病的化合物和及其药物组合物

Country Status (5)

Country Link
US (2) US9796719B2 (https=)
EP (1) EP3010922B1 (https=)
JP (1) JP6435323B2 (https=)
CN (1) CN105339370B (https=)
WO (1) WO2014202458A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501870D0 (en) * 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
WO2016144706A2 (en) * 2015-03-11 2016-09-15 Pharmakea, Inc. Autotaxin inhibitor compounds and uses thereof
AU2016270373A1 (en) 2015-06-05 2018-01-04 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
US20200253959A1 (en) 2017-08-09 2020-08-13 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
CN109384803B (zh) * 2017-08-09 2021-08-31 广州市恒诺康医药科技有限公司 Atx抑制剂及其制备方法和应用
CN111620865B (zh) * 2018-02-14 2021-06-11 苏州信诺维医药科技股份有限公司 一种杂环化合物、其应用及含其的药物组合物
CA3108809C (en) * 2018-05-24 2023-08-29 Guangzhou Henovcom Bioscience Co., Ltd. Heteroaromatic compounds, pharmaceutical compositions and uses thereof
WO2019228403A1 (en) 2018-05-29 2019-12-05 Fronthera U.S. Pharmaceuticals Llc Autotaxin inhibitors and uses thereof
IL279702B2 (en) 2018-07-27 2024-05-01 Mitsubishi Tanabe Pharma Corp 3, 5-disubstituted pyridine and 3, 5-disubstituted pyridazine derivatives and pharmaceutical use of same
BR112021005445A2 (pt) * 2018-10-29 2021-06-15 Boehringer Ingelheim International Gmbh piridazinas
IL284994B2 (en) 2019-02-01 2024-10-01 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Pyrrolopyrimidine derivative and use thereof
TW202110831A (zh) * 2019-06-04 2021-03-16 大陸商江蘇恆瑞醫藥股份有限公司 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
US11465982B2 (en) 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
CN114127054B (zh) * 2019-07-22 2024-04-09 勃林格殷格翰国际有限公司 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物
US11485727B2 (en) 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
CN112457296B (zh) 2019-09-06 2023-11-07 武汉人福创新药物研发中心有限公司 嘧啶类化合物及其制备方法
CN112778334B (zh) * 2019-11-07 2022-04-15 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
JP2023505155A (ja) * 2019-12-04 2023-02-08 アプティニックス インコーポレイテッド 神経変性疾患に関連する認知障害を治療する方法
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
US20230159931A1 (en) * 2020-04-24 2023-05-25 Cornell University Targeting the palmotylation/depalmotylation cycle to treat inflammatory diseases
US20230295159A1 (en) * 2020-07-09 2023-09-21 Suzhou Ark Biopharmaceutical Co., Ltd. Atx inhibitor, and preparation method therefor and use thereof
CN114315825A (zh) * 2020-09-30 2022-04-12 江西济民可信集团有限公司 吡啶并咪唑衍生物及其制备方法和应用
WO2022074459A2 (en) * 2020-10-06 2022-04-14 Ildong Pharmaceutical Co., Ltd. Autotaxin inhibitor compounds
EP4242208A4 (en) * 2020-11-04 2025-01-15 Xizang Haisco Pharmaceutical Co., Ltd. DEUTERATED DERIVATIVE USED AS ATX INHIBITOR, AND ITS APPLICATION
WO2022100727A1 (zh) * 2020-11-16 2022-05-19 广州市恒诺康医药科技有限公司 咪唑并噻唑类化合物、其药物组合物及其用途
JP2024502337A (ja) 2021-01-05 2024-01-18 ザイダス ライフサイエンシズ リミティド オートタキシンの新規阻害剤
IL313087B2 (en) * 2021-11-25 2026-02-01 Shanghai Jemincare Pharmaceuticals Co Ltd ATX inhibitors, their preparation method, their application and their medicinal salt

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131991A1 (en) * 2006-05-15 2007-11-22 Galapagos N.V. Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
WO2008138842A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
CN101454326A (zh) * 2006-05-31 2009-06-10 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的三唑并吡嗪化合物
CN102036997A (zh) * 2008-05-07 2011-04-27 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的稠合吡嗪化合物
WO2011054922A1 (en) * 2009-11-05 2011-05-12 Galapagos Nv Salts of fused pyrazine compounds, useful for the treatment of degenerative and inflammatory diseases.
CN102105471A (zh) * 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物
CN102216299A (zh) * 2008-12-01 2011-10-12 默克专利有限公司 作为自体毒素抑制剂的2，5-二氨基取代的吡啶并[4，3-d]嘧啶化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2029602E (pt) * 2006-05-31 2010-07-08 Galapagos Nv Compostos de triazolopirazina uteis para o tratamento de doenãas degenerativas e inflamatërias
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
DE102008028905A1 (de) * 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
CA2834166A1 (en) * 2011-04-29 2012-11-01 Amgen Inc. Bicyclic pyridazine compounds as pim inhibitors
EP2714680B1 (en) * 2011-05-27 2015-11-25 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
RU2675818C2 (ru) 2013-03-14 2018-12-25 Галапаго Нв Новые соединения и фармацевтические композиции, их содержащие, для лечения воспалительных расстройств

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131991A1 (en) * 2006-05-15 2007-11-22 Galapagos N.V. Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
CN101454326A (zh) * 2006-05-31 2009-06-10 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的三唑并吡嗪化合物
WO2008138842A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
CN102036997A (zh) * 2008-05-07 2011-04-27 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的稠合吡嗪化合物
CN102105471A (zh) * 2008-07-25 2011-06-22 加拉帕戈斯股份有限公司 用于治疗变性和炎性疾病的新化合物
CN102216299A (zh) * 2008-12-01 2011-10-12 默克专利有限公司 作为自体毒素抑制剂的2，5-二氨基取代的吡啶并[4，3-d]嘧啶化合物
WO2011054922A1 (en) * 2009-11-05 2011-05-12 Galapagos Nv Salts of fused pyrazine compounds, useful for the treatment of degenerative and inflammatory diseases.

Also Published As

Publication number Publication date
US20180127425A1 (en) 2018-05-10
JP2016525072A (ja) 2016-08-22
US20160214986A1 (en) 2016-07-28
CN105339370A (zh) 2016-02-17
EP3010922A1 (en) 2016-04-27
JP6435323B2 (ja) 2018-12-05
WO2014202458A1 (en) 2014-12-24
EP3010922B1 (en) 2017-03-15
US9796719B2 (en) 2017-10-24

Similar Documents

Publication Publication Date Title
CN105339370B (zh) 用于治疗炎症性疾病的化合物和及其药物组合物
JP6517976B2 (ja) 炎症性障害の治療のための化合物及びその医薬組成物
WO2013117645A1 (en) Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases
HK1219730B (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant